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1. Introduction 
Cardiovascular disease remains the leading cause of death in industrialized nations. Type 2 
diabetes confers cardiovascular risk comparable to a previous myocardial infarction, and is 
the most common cause of chronic kidney disease. Diabetes and hypertension account for 
2/3 of cardiovascular risk [1]. Over 75% of adults with diabetes are  hypertensive, or being 
treated with hypertensive medications [2]  In patients with type 1 diabetes, the presence of 
hypertension signals significant kidney damage whereas in patients with type 2 diabetes, 
hypertension is usually present at the time of diagnosis [2]. On the other hand, many 
hypertensive treatments, specifically diuretics, worsen glucose control; the overall 
implications of this are as yet unclear [2]. Because of the singular risk resulting from the 
combination of diabetes and hypertension, significant effort has been expended to improve 
patient outcome. While several recent excellent reviews address different aspects of this 
issue [1-3], we will evaluate the management of hypertension in diabetes, particularly from 
the perspective of managing hypertension in metabolic syndrome. We will evaluate the 
metabolic effects of different agents used for blood pressure control, consider specific 
patient-related issues, discuss shortcomings of recent trials, and consider possible future 
directions in genetic analyses.  
There are over 65 million hypertensives in the United States [4]. Unfortunately, the 
pharmacological treatment of these individuals has had less than the predicted benefit on 
coronary heart disease (CHD) mortality [5-7]. For many years, It has been postulated that 
treatment with some antihypertensives might have metabolic and other untoward effects 
that negate some of the benefits of blood-pressure lowering [5, 8]. This may be particularly 
true for individuals with the metabolic syndrome, a constellation of anthropometric and 
metabolic abnormalities that includes central obesity, hypertension, elevated levels of 
fasting glucose and triglycerides, low concentrations of high-density lipoprotein cholesterol 
(HDL-C), and insulin resistance which is associated with increased cardiovascular disease 
morbidity and mortality [9-11]. Of the five diagnostic criteria for metabolic syndrome, 
hypertension and central obesity are most frequently present [12, 13]. 
Why is this increasingly important in the US?  The prevalence of obesity has doubled in the 
US in the past 20 years [14]; the number of extremely obese individuals with a BMI >35 
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kg/m2 is almost 5% of the population. Obese compared with normal weight individuals 
have a 3.5 fold increased risk of developing hypertension while up to 60% of obese 
individuals have hypertension [15, 16]. The association between obesity and hypertension 
may be related to greater insulin resistance, leptin-mediated enhancement of sympathetic 
activity, sodium and fluid retention, and adipocyte-mediated effects on angiotensin II and 
atrial natriuretic peptide levels [17]. Patients with hypertension have an increased 
prevalence of type 2 diabetes mellitus and impaired glucose tolerance [18, 19]. Patients with 
mild hypertension also have lower HDL-cholesterol concentrations and higher HDL 
catabolic rates; these findings appear to correlate with insulin resistance [20]. With 
hypertension, obesity and diabetes mellitus increasing in frequency, it is not surprising that 
the age-adjusted prevalence of metabolic syndrome in the general US population is 24.0% 
for men and 24.3% for women [21].  
Lifestyle therapies for patients with metabolic syndrome, including weight reduction, 
increased physical activity, decreased sodium and alcohol reduction, reduced consumption 
of saturated and trans fats and cholesterol, and increased consumption of fresh fruits and 
vegetables are extremely important. Studies have shown that dietary changes can lower 
blood pressure and improve other metabolic syndrome components [22, 23]. Increased 
exercise can also lower blood pressure [24].  
Despite the benefits of lifestyle changes, pharmacological treatment of hypertension is 
frequently needed. However, the choice of an antihypertensive is controversial. Studies 
suggest that treatment with different antihypertensive drug classes may have varied effects 
on glucose and lipid metabolism [25]. Changes in insulin sensitivity are associated with 
adverse effects on glucose control [26, 27]. Increases in blood glucose during 
antihypertensive treatment have been found to be a predictor of myocardial infarction [28]. 
Insulin resistance is also associated with endothelial dysfunction, which is also predictive of 
future cardiovascular events [29]. Lind et al. have reported that these metabolic effects 
persist with long-term (> 2-3 years) antihypertensive treatment [30]. In this context, it would 
be important to choose antihypertensives that have the least adverse metabolic effects, 
particularly in patients with the metabolic syndrome.  
In addition, to the choice of antihypertensive agent, the degree of blood pressure lowering is 
important. The lower the goal, the greater the number of antihypertensive agents needed, 
the cost of these agents and the potential for side effects. Patient adherence declines with the 
number of medications required. It is important to balance these drawbacks with 
improvement in clinical outcomes. 
2. Evidence for blood pressure goals  
By some standards, the Action to Control Cardiovascular Risks in Diabetes Study 
(ACCORD) was a disappointment. ACCORD was a large well-designed trial that attempted 
to study the effects of tight control of blood sugar, hypertension, and lipids in patients with 
type 2 diabetes mellitus [31]. In the original report, published in the New England Journal of 
Medicine in 2008, 10,251 patients (mean age, 62.2 years and median glycated hemoglobin 
level of 8.1%) were assigned to receive intensive therapy targeting a glycated hemoglobin 
level below 6 % or standard therapy targeting a level from 7.0 to 7.9% [31]. Of these patients, 
38% were women and 35% had had a previous cardiac event. The primary outcome was a 
composite of nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular 
causes. Details of the glycemic and lipid control arms have been presented [31, 32], and 
analyzed [33] elsewhere. The results of the blood pressure arm will be focused on below.  
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4,733 participants in ACCORD were randomly assigned to intensive blood pressure therapy, 
targeting a systolic pressure of <120 mm Hg or standard therapy targeting a systolic 
pressure of <140 mm Hg [34]. Again, the primary composite outcome was nonfatal 
myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean 
follow-up was 4.7 years. The annual rate of the primary outcome was 1.87% in the intensive 
therapy group and 2.09% in the standard therapy group (P=0.20). The annual death rates 
from any cause were 1.28% and 1.19% in the two groups, respectively (P=0.55). The annual 
stroke rate, a pre specified secondary outcome, were 0.32% and 0.53% in the two groups, 
respectively (P=0.01). Serious adverse events attributed to antihypertensive treatment 
occurred in 77 of the 2,362 participants in the intensive therapy group (3.3%) and 30 of the 
2,371 participants in the standard therapy group (1.3%) (P <0.01). There were more subjects 
with a decrease of their estimated glomerular filtration rate to less than 30 ml per minute per 
1.73 m2 of body surface area in the intensive therapy group than in the standard therapy 
group (99 versus 52 events, P <0.01).  
The interpretation of the ACCORD blood pressure results is complicated by a number of 
factors. The event rate observed in the standard therapy group was almost 50% lower than 
expected. This result may have been a consequence of the frequent use of statins and inclusion 
criteria that directed participants with dyslipidemia into the ACCORD lipid trial, leaving 
participants who were at lower risk in the blood pressure trial. Additionally, ACCORD may 
have been under powered and of too short of duration to discern a benefit [35]. In ACCORD 
the confidence intervals were wide and do not exclude a 27% benefit for the intensively treated 
group for the primary end point at 5 years. It is also possible that the effects of intensive blood 
pressure control in the setting of good lipid and glucuose control may differ for 
cerebrovascular and coronary events. That is, intensive blood pressure control is more likely to 
prevent strokes than myocardial infarctions. In a classic meta analysis, Collins and colleagues 
found that the decrease in stroke from antihypertensive therapy in clinical trials was what 
would be predicted based on epidemiologic studies [5]. However the decrease in coronary 
artery disease (CAD) was about one-half of what would be predicted.  
The ACCORD blood pressure study population was relatively healthy and thus unlikely to 
have a high proportion of events. The 5,000 patients pre study mean systolic blood pressure 
was 140 mm Hg of mercury. Their mean age was 62 years and nearly one-half were women. 
The mean serum creatinine of this group was 0.9 mg per deciliter and 87% were receiving 
antihypertensive medication at the time of enrollment. The average glycated hemoglobin 
level was 8.3% and the mean body mass index was 32 kg/m2. The mean urinary 
albumin/creatinine ratio was 14.3. Although these middle-aged patients were overweight 
and had type 2 diabetes, they had no substantial evidence of kidney disease and appeared to 
have good blood pressure control. At the 12 month visit, nearly 90% of patients were 
receiving a drug that blocks the renin angiotensin system, while more than 50% received ǃ-
blockers, about 40% received a calcium channel blocker, and nearly 60% received statins and 
platelet inhibitors. One might conclude that at 5 years, people with type 2 diabetes who 
have good quality cardiovascular care and no evidence of kidney disease do not have a 
major therapeutic advantage from lowering systolic blood pressure to <120 mm Hg. A 
longer follow-up time might be necessary to see a benefit of lowering blood pressure to this 
degree.  
The negative outcome in ACCORD in the intensely treated blood pressure arm might also 
be attributed to the lack of effect on ischemic heart disease events that are included in the 
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composite end point. In the intensive treatment arm, investigators were advised to begin a 
regimen of an ACE inhibitor or angiotensin receptor blocker (ARB) plus a thiazide-like 
diuretic, chlorthalidone [36]. The same requirements were not given to the less intensively 
treated group. This resulted in the intensively treated group receiving roughly twice as 
much chlorthalidone as the less intensively treated group. That is, diuretics were used 83% 
and 89% of the time at 12 months and at the last visit, respectively, in the intensively treated 
group while in the standard care group, the usage was 52% and 56%. This amount of 
diuretic usage could account for the greater prevalence of hypokalemia seen in the intensive 
treatment group (P=.01) [8]. Data from the Systolic Hypertension in the Elderly Program 
(SHEP Trial), suggest that this degree of hypokalemia would essentially eliminate the 
projected benefit on ischemic heart disease events from the blood pressure reduction 
achieved in ACCORD [37]. 
The United Kingdom Prospective Diabetes Study (UKPDS) was a randomized, prospective, 
multicenter trial that, in addition to its attention to glycemic control, randomized patients to 
a "tight" blood pressure control regimen including ACE inhibition (captopril) or ǃ-blocker 
therapy (atenolol), or "less-tight" blood pressure control that excluded these agents [38]. For 
tight compared to less-tight control of blood pressure, there were dramatic and significant 
improvements in risk reduction in any diabetes-related end point (24%), diabetes-related 
death (32%), stroke (44%), and microvascular disease (37%) [39]. In UKPDS, the goal blood 
pressure for the tight group was <150/85, and for the less-tight, <180/105. The mean 
achieved blood pressures were 144/82 and 154/87 mm Hg for the tight and less-tight 
groups, respectively. Of note, the mean blood pressure, at entry, was 160/94. 
The Steno-2 Study reported a post interventional benefit for micro- and macrovascular 
complications of diabetes that persisted after risk factor intervention, although within-trial 
differences in risk factors for these complications (e.g., blood pressure) diminished, 
suggesting a persistent effect of earlier improvement in risk factors—a so-called legacy effect 
[40]. The diminishment in the difference of risk factors resulted from different phenomena:  
In the intensively-treated group, systolic blood pressure rose slightly in follow-up, while it 
remained stable in the conventionally-treated group. On the other hand, diastolic blood 
pressure remained low in the intensively-treated group, while it continued to fall in the 
conventional group. Recently, the survivor cohort of UKPDS was evaluated after a 10-year 
post-interventional follow-up that examined whether a continued benefit of improved blood 
pressure control could be demonstrated [41]. In contrast to the Steno-2 Study, the benefits of 
previously-attained improved blood pressure control were not sustained when between-
group differences were lost. There were no differences in blood pressure control in patients 
treated with captopril or atenolol. Again, in contrast to the Steno-2 findings, in both "tight" 
and "less-tight" groups, blood pressures actually improved in follow-up and were 
indistinguishable, in the mid-140's/high 70's range. Thus, it may be that it was the improved 
blood pressure control in the "less-tight" group, as opposed to treatment failure in the "tight" 
group that decreased treatment differences. 
INVEST (INternational VErapamil-SR/Trandolapril STudy) studied patients with multiple 
risk factors [42]. Of the 22576 participants (who were recruited because they had both 
coronary disease and hypertension), 6400 (28%) had diabetes. These patients were evaluated 
for the effects of achieved systolic blood pressure on the risk of cardiovascular events. 
Patients were categorized into three groups on this basis: tight (<130), usual (130-<140), and 
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uncontrolled (≥140) mm Hg achieved systolic blood pressure. Tight control was not 
associated with improved cardiovascular outcome compared to usual control. Uncontrolled 
patients did worse. A similar post hoc analysis of INVEST compared participants with and 
without peripheral arterial disease (PAD) [43]. 41.4% of PAD patients and 26.6% of those 
without PAD had diabetes (P<0.001). A J-shaped relationship was observed for patients 
with PAD:  the hazard ratio for the primary outcome (all-cause death, nonfatal myocardial 
infarction, or nonfatal stroke), when plotted against achieved blood pressure, showed fewest 
events at blood pressures of 135-145/60-90); this was more pronounced for systolic blood 
pressure. Patients without PAD did not manifest this J-shaped association with systolic 
blood pressure. Patients with or without diabetes were not analyzed separately.  
What lessons can be drawn about goal blood pressure for patients with metabolic syndrome 
from the studies cited above?  It does not appear that the notion “the lower the better” 
applies to blood pressure in patients with type 2 diabetes, especially in those who are 
nonsmokers, have reasonable glycemic control and are taking statins and anti-platelet 
therapy. In ACCORD, lowering systolic blood pressure from the mid-130s to 120 mm Hg 
did not further reduce cardiovascular events, with the possible exception of stroke, which 
should be a pre-specified primary endpoint in future blood pressure clinical trials that aim 
for such low blood pressures. The price of lowering blood pressure to this degree in 
ACCORD was generally one additional antihypertensive and it was accompanied by a 
significantly higher rate of serious adverse events. Thus, it appears that lowering systolic 
blood pressure to 120 mm Hg is not warranted and recommendations to aim for a systolic 
blood pressure of <140 mm Hg and a diastolic blood pressure, based on the HOT and 
UKPDS results presented above, of <80 mm Hg are best supported by current evidence. 
However, it must be remembered that longer term follow-up of ACCORD may lead to 
different conclusions.  
3. Effect of different classes of antihypertensive on components of the 
metabolic syndrome 
Thiazide diuretics 
Several studies have suggested an association between thiazide use and the development of 
glucose intolerance and diabetes. In the Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT), the group randomized to chlorthalidone had a 
higher proportion of patients who developed diabetes than those randomized to either 
amlodipine or lisinopril [44]. In the Systolic Hypertension in the Elderly Program (SHEP), 
there was not a statistically significant increased rate of diabetes comparing chlorthalidone 
with placebo after 3 years, but in a later 14.3 year follow-up, 13% of patients given 
chlorthalidone versus 8.7% of those given placebo ( P < 0.0001) developed diabetes [45, 46]. 
In a large study of hypertensive men and women, after adjustment for BMI, those taking 
compared with those not taking thiazide diuretics had an increased risk of developing 
diabetes [47]. We studied 2624 patients who were initiated on thiazide diuretics [48]. 
Increasing values of fasting blood glucose (FBG) were associated with increasing baseline 
BMI and there was a positive association between a new diagnosis of diabetes after thiazide 
initiation and increasing BMI that ranged from 2.7% in the first quartile of BMI to 6.5 % in 
the heaviest quartile. Studies have also found an association between blood glucose and 
thiazide dose [49, 50]. A review of nine studies using a relatively low dose (12.5 mg) of 
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hydrochlorothiazide as monotherapy found that increases in glucose levels were nether 
clinically nor statistically different from baseline levels [51]. Interestingly, in most of these 
studies, there was little relationship between blood pressure effects and diuretic dose. An 
association between hypokalemia and glucose intolerance, even in euglycemic subjects, has 
been described [48, 52, 53]. In patients on thiazides, hypokalemia has been associated with 
higher FBG that improved after replacement of potassium [54]. 
Thiazide diuretics may impair glucose metabolism by decreasing peripheral insulin 
sensitivity, resulting in increasing insulin secretion [55-57]. Our results suggest that the 
probability of developing new diabetes after thiazide initiation is associated with increasing 
BMI [48]. This association is supported by our previous work (DS). In 139 patients 
randomized to 50 mg of hydrochlorothiazide for 2 months, there was an increasing change 
from baseline serum insulin levels as a consequence of increasing body mass index [18].  
Diuretics may also affect lipid metabolism. In general, high dose diuretics have been 
reported to increase serum total cholesterol by about 4% and serum LDL-cholesterol by 10% 
[51]. In ALLHAT, the group randomized to chlorthalidone had a higher total cholesterol 
levels at 2 years by about 3 mg/dL (~1.5%) than those randomized to either amlodipine or 
lisinopril (P<.001 for both); this difference diminished at 4 years for amlodipine, although 
not for lisinopril [44]. In SHEP, there was a small but significant increase of total cholesterol 
(P<.01) and decrease of HDL-cholesterol (P<.01) comparing chlorthalidone to placebo after 3 
years. In another study, there was a 10% increase (P<.05) in fasting triglycerides from 
baseline after 16 weeks of treatment with hydrochlorothiazide compared with those treated 
with valsartan [58]. In a cross-sectional study from Brazil, hypertensive patients treated with 
diuretic monotherapy had a more atherogenic lipid profile (increased total- and LDL-
cholesterol and apolipoprotein B) than patients on combined diuretic-based medication 
regimes, suggesting that the nondiuretic therapy had a mitigating effect on the lipid profile 
[59]. The mechanism of diuretic induced dyslipidemia may be related to increased hepatic 
production, in part mediated by a reduction in insulin sensitivity [51]. 
The impact of the ALLHAT findings on clinical recommendations is controversial [44]. On 
the one hand, are the metabolic abnormalities associated with chlorthalidone noted above. 
On the other hand, is the fact that those patients randomized to chlorthalidone had virtually 
identical clinical outcomes compared with lisinopril and amlodipine in terms of the primary 
outcome: the occurrence of coronary heart disease and nonfatal myocardial infarction. For 
secondary outcomes, chlorthalidone was superior to amlodipine in preventing heart failure, 
and compared with lisinopril, chlorthalidone was superior as a means to lower blood 
pressure and prevent stroke, as well as to prevent combined cardiovascular disease and 
perhaps heart failure. At present, we believe that thiazide diuretics (especially 
chlorthalidone) are alternative first choice agents in nondiabetic patients with metabolic 
syndrome but should be used carefully in patients with elevated BMI. In those instances 
where patients become diabetic after initiation of thiazides, we recommend that an 
alternative antihypertensive class be used rather than treat the metabolic consequences of 
thiazides with diabetic medications. In diabetics, thiazides diuretics may also be used. 
However, in those instances where initiation of these agents results in a worsening of 
glucose control, again, we would recommend the use of alternative agents. 
┚-Blockers 
The place of ǃ-blockers in the treatment of hypertension is controversial. This is partly based 
on the finding that these agents are less effective in reducing the incidence of stroke [60, 61], 
myocardial infarction and death than are other antihypertensives [61, 62]. These findings are 
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complicated by the diversity of ǃ-blockers that have varying pharmacological properties. 
The mechanisms of action and pathophysiological effects vary widely among the 
nonselective, selective, and vasodilating ǃ-blockers. Added to this variation are the effects of 
agents such as carvedilol that have both non-selective ǃ-blocker and ǂ1-blocking properties.  
In several studies of non-selective [63] or ǃ1 selective [64-66] ǃ-blockers, there was a 
significant decrease in insulin sensitivity in hypertensive patients. This decrease in insulin 
sensitivity may have a deleterious effect on glycemic control in patients with hypertension 
or in those with type 2 diabetes mellitus. In patients with the metabolic syndrome, decreases 
in insulin sensitivity may be initially compensated for by increases in insulin secretion by 
pancreatic ǃ-cells. However, after a period of time, the ǃ-cells are no longer able to keep up 
with the increasing insulin demands and increase in blood glucose, and potentially overt 
diabetes, may result. 
In the Atherosclerosis Risk in Communities Study (ARIC), hypertensives treated with ǃ-
blockers had a 28% increased risk of developing type 2 diabetes compared with patients 
taking no medication [67]. In INVEST, hypertensives randomized to verapamil-based 
therapy had a 15% lower incidence of new onset diabetes than subjects in the atenolol group 
[68]. Other studies have found similar results comparing ǃ-blockers to either the 
angiotensin-converting enzyme (ACE) inhibitors [69] or angiotensin receptor blockers 
(ARBs) [70] . 
Several actions of ǃ-blockers may affect insulin sensitivity and glycemic control. ǃ-blockers 
block pancreatic ǃ2 receptors resulting in an inhibition of insulin secretion that results in an 
impairment of glucose metabolism leading to hyperglycemia [55]. This effect is more 
pronounced with nonselective ǃ-blockers, but can also be seen with higher doses of selective 
ǃ-blockers [71]. ǃ-blockers have been associated with weight gain leading to the metabolic 
syndrome due to the weight gain itself as well as through obesity mediated impairment of 
insulin sensitivity [72, 73]. Insulin promotes vasodilatation resulting in increased blood flow 
in skeletal muscles [74]. During treatment with nonselective ǃ-blockers, unopposed ǂ1-
activity causes vasoconstriction leading to decreased blood flow to muscles [75]. This may 
result in decreased insulin-stimulated glucose uptake and insulin resistance. In insulin-
resistant states such as type 2 diabetes and obesity, endothelium-dependent insulin-
mediated vasodilatation is impaired which may also lead to insulin resistance [74, 76]. In the 
metabolic syndrome, the interaction of obesity and hyperglycemia with ǃ-blockers may lead 
to more severe skeletal vasoconstriction resulting in worsening insulin resistance.  
Newer ǃ-blockers that cause vasodilatation appear to not have the deleterious effects on 
insulin sensitivity and glucose metabolism described above. Carvedilol, as noted above, a 
non-selective ǃ-blocker with ǂ1-blocking properties has been found to improve insulin 
sensitivity. In 72 hypertensive patients without diabetes, carvedilol compared with 
metoprolol resulted in a 14% increase in insulin sensitivity while metoprolol led to a 
decrease [77]. A study comparing carvedilol with atenolol had similar results [78]. In two 
trials comparing carvedilol with metoprolol, the Glycemic Effects in Diabetes Mellitus: 
Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial and the Carvedilol or 
Metoprolol European Trial (COMET), the carvedilol group had decreases in both insulin 
resistance and HbA1c while the metoprolol group had an increase in HbA1c and no change 
from baseline in insulin resistance (GEMINI) [79], and improved rates of survival and 
cardiovascular hospitalizations (COMET). In GEMINI, although blood pressure was similar 
between groups, progression to microalbuminuria was less frequent with carvedilol than 
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with metoprolol. This may reflect an antioxidant effect specific to carvedilol [80]. Findings 
from GEMINI also suggest that the use of vasodilating ǃ-blockers may not result in weight 
gain [81]. In addition to carvedilol, vasodilating ǃ-blockers available in the US are labetalol 
and nebivolol. 
The effects of ǃ-blockers on lipid metabolism are modest, but also vary according to ǃ-
blocker type. Nonselective ǃ-blockers increase serum triglycerides and tend to lower HDL-
cholesterol, while cardioselective ǃ1-blockers and ǃ-blockers without intrinsic 
sympathomimetic activity have qualitatively similar but less pronounced effects. These 
effects may be, at least in part, mediated by weight gain. In the Losartan Intervention for 
Endpoint (LIFE) reduction study, HDL- cholesterol decreased more and remained lower 
during the first 2 years of the study in those treated with the ǃ1-selective blocker atenolol 
compared with those randomized to losartan [82]. In a study comparing atenolol with 
metoprolol, treatment increased serum triglycerides by 21% and 29%, respectively, 
compared with placebo, and decreased HDL-cholesterol by about 7% [65]. In a recent study 
comparing the effects of  carvedilol and metoprolol on serum lipids in diabetic hypertensive 
patients, both drugs decreased HDL-cholesterol and increased triglycerides [83]. Comparing 
the two drugs, there was no difference in HDL-cholesterol levels but carvedilol resulted in 
statistically significant lower levels of total cholesterol, triglycerides and non-HDL 
cholesterol. 
Based on the above, it appears logical in patients with the metabolic syndrome, who require 
a ǃ-blocker, to treat them with one of the newer vasodilating agents that have neutral or 
beneficial metabolic effects. That said, at present, there are few studies that directly compare 
the different types of ǃ-blockers on hard clinical outcomes, especially total mortality. 
Adding to this uncertainty is the fact that newer ǃ-blockers are far more expensive than 
older agents such as atenolol and metoprolol. 
ACE inhibitors and angiotensin receptor blockers  
Over20 years ago, the ACE inhibitor captopril was shown to benefit glucose metabolism and 
insulin resistance, particularly in comparison to thiazides [55]. ACE inhibitors and ARBs 
may exert beneficial effects on glycemic control through a variety of mechanisms related to 
the inhibition of angiotensin II. Angiotensin II activates the sympathetic nervous system 
resulting in impairment of insulin secretion and peripheral glucose uptake [84]. Angiotensin 
II also impairs pancreatic blood flow and enhances insulin resistance, while ACE inhibitors 
directly improve insulin sensitivity primarily in skeletal muscle [85].  
The magnitude of the beneficial effect of ACE inhibitors on glucose metabolism is 
demonstrated by clinical trials such as the HOPE (Heart Outcomes Prevention Evaluation) 
Study, which demonstrated a reduced rate of new onset diabetes mellitus in patients taking 
the ACE inhibitor ramipril [86]. Angiotensin II has a central role in glucose metabolism, in 
addition to its effect on the sympathetic nervous system and aldosterone release, that 
includes activation of insulin-stimulated mitogenic pathways that promote vascular smooth 
muscle proliferation (MAPK), but suppression of pathways involved in glucose transport 
(PI-3K) [87-91]. Nitric oxide synthase may play a key role in mediating angiotensin effects 
[92], as might oxidative stress [93, 94]. In an animal model of atherosclerosis, (the Watanabe 
Heritable Hyperlipidemic Rabbit), the combination of the aldosterone antagonist eplerenone 
with the ACE inhibitor enalapril led to additive protective effects on endothelial function 
and atherosclerotic changes [95]. In patients with documented atherosclerosis, ramipril 
lowered highly sensitive C-reactive protein [96]. This “crosstalk” between vascular growth 
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and metabolic pathways may explain many of the defects in the metabolic syndrome. In 
patients with cardiac allograft vasculopathy, ACE inhibitors appear to be associated with 
plaque reduction [97].  
While many of the studies reviewed above have grouped ACE inhibitors and ARBs together 
as generally having similar mechanisms of action, there are differences both among ACE 
inhibitors and between ACE inhibitors and ARBs. The ACE inhibitors enalapril and 
perindopril were compared in normotensive patients with coronary artery disease; neither 
agent lowered blood pressure, but perindopril was superior in terms of anti-oxidant, 
antithrombotic, and profibrinolytic activities [98]. In mild hypertensive patients, zofenopril 
(a sulfhydryl-containing ACE inhibitor) lowered LDL-cholesterol, oxidized LDL, peroxide, 
and increased flow-mediated dilation (a marker of endothelial function) compared to 
ramipril (a carboxylic-containing ACE inhibitor), and atenolol. Blood pressure was 
comparable in all three groups [99].  
ARBs do not appear to be active on these pathways. Furthermore, there may be differences 
among ARBs. Telmisartan, for example, seems to activate insulin-sensitizing PPAR-Ǆ 
pathways [100], with benefit in preclinical and clinical studies [101, 102]. Studies in 
nondiabetic hypertensive patients shown improvement in insulin sensitivity, measured by 
the homeostasis model assessment (HOMA) technique, when telmisartan was used alone; 
this effect was blunted when the drug was used in combination with the dihydropyridine 
calcium channel blocker nisoldipine [103]. This benefit occurred without changes in serum 
values of the adipose tissue-derived cytokine, adiponectin. Similar results on insulin 
sensitivity, also assessed by HOMA, were reported in a study of hypertensive type 2 
diabetic patients [104]. Other investigators have found that telmisartan is associated with 
decreased vascular inflammation, reduced visceral fat, and increased adiponectin [105], 
while others have reported that telmisartan, compared to candesartan lowered fasting 
plasma glucose and body weight, and increased adiponectin. Diastolic blood pressure was 
comparably reduced in both treatment groups compared to control [106]. Losartan, another 
ARB, has an uricosuric effect that may be of benefit in cardiovascular risk [107].  
A recent development in this treatment approach includes renin inhibitors, that improve 
blood pressure but have not been studied for their metabolic effects [108, 109], although 
recent data suggests an improvement (reduction) in atherosclerosis progression with 
aliskerin [109]. 
Calcium Channel Blockers 
Calcium channel blockers (CCBs) may impair insulin release, but this effect on glucose 
metabolism appears to be balanced by their action to increase peripheral glucose uptake [110, 
111]. CCBs have been shown to have no significant adverse metabolic effect [112, 113], or a 
slight negative effect [114]. Some short-term studies have even suggested a slight positive 
effect on glucose and insulin metabolism [66]. In one study, long-acting CCBs have been 
reported to have no significant metabolic effect [115],  while an early study comparing short-
acting nifedipine to atenolol showed improvement in postprandial glucose (suggesting 
improved insulin action since concurrent insulin concentrations were unaffected) and 
triglyceride values, as well increased HDL values, with the former agent [66]. 
Dihydropyridine CCBs (i.e., nifedipine) have no antiproteinuric effect, unlike the 
benzothiazepine diltiazem and the phenylalkylamine verapamil, and do not slow the 
progression of diabetic nephropathy [116]. This may have particular relevance in these high-
risk patients. In a study of 12 550 nondiabetic hypertensives, subjects taking ǃ -blockers, but 
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not those taking thiazides, ACE inhibitors or calcium channel blockers, were at increased 
risk of developing diabetes [67]. In a study of 16176 coronary patients with hypertension, 
CCB-based therapy (verapamil SR) was less likely to result in the development of newly 
diagnosed diabetes mellitus than ǃ-blocker (atenolol) based treatment [68]. In this study, 
addition of the ACE inhibitor trandolapril to verapamil SR decreased diabetes mellitus risk 
and the addition of hydrochlorothiazide to atenolol increased risk. In hypertensive patients 
with chronic kidney disease (stage not defined, but baseline creatinine  ~1.6), treated with 
either telmisartan or amlodipine, creatinine, proteinuria, IL-6, MMP-9, and total cholesterol 
all declined, while 24 hour urinary creatinine clearance improved with  telmisartan but not 
with amlodipine, despite comparable blood pressure reduction [117]. In another trial, 
treatment with the ARB valsartan was associated with a greater reduction in new onset 
diabetes compared with amlodipine [118].  
CCBs appear to have systemic antiinflammatory effects that may be additive with other 
antihypertensive agents [119-121]; there may also be improvement (reduction) in oxidized 
LDL-cholesterol levels [122]. 
┙-Antagonists 
Prazosin, using fasting and postprandial glucose and insulin data, has been found to 
improve insulin sensitivity in patients with essential hypertension [123]. Pollare, et al. 
similarly reported that prazosin directly improved insulin sensitivity [124]. Prazosin has 
also been reported to improve HDL kinetics [125]. Terazosin appears to have no effect on 
glucose tolerance or insulin sensitivity [126], although men with benign prostatic 
hypertrophy treated with terazosin have improved lipid values [127]. No data is available 
for tamsulosin.  
Doxazosin improved glucose and lipid metabolism in diabetic patients and in patients with 
impaired glucose tolerance [128, 129]. It has also been reported to improve insulin 
resistance, and increase LDL particle size [130, 131]. Doxazosin has also been described as 
acting synergistically with acarbose in patients with impaired glucose tolerance [132]. When 
doxazosin was added to existing therapies in patients with inadequately treated 
hypertension and impaired glucose metabolism, blood pressure control was improved in 
over 1/3 of cases, with concomitant improvement in glucose and lipid parameters and a 
reduction in atherosclerotic cardiovascular disease risk [133]. Similar metabolic benefit 
occurred when doxazosin was compared to bendrofluazide in hypertensive patients [134], 
and when doxazosin was compared to atenolol [135]. Doxazosin also reduced serum 
concentrations of oxidized LDL-cholesterol (a more atherogenic lipid fraction) in 
hypertensives [136]. Urapidil has no major effect on glucose metabolism, but favorably 
affects another cardiovascular risk marker, fibrinogen [137]. 
Central-acting ┙-agonists 
Clonidine, which acts by binding to central ǂ-2-adrenergic and imidazoline receptors, 
appears to be metabolically neutral in terms of glucose and insulin effects [138]; more 
recently developed imidazoline agonists have not been widely studied from this perspective 
[139]. However, rilmenidine has recently been reported to have similar blood pressure, 
lipid, and glucose effects to lisinopril in hypertensive women with metabolic syndrome 
[140].  
The metabolic effects of antihypertensives are summarized in the Table. 
www.intechopen.com
 
Managing Hypertension in Patients with Diabetes 
 
217 
Class of agent Glucose and 
insulin effects
Lipid effects
 Glucose IR Total Chol HDL-C LDL-C TG 
Thiazide (inc. 
chlorthalidone)1 
↑ ↑ ↑ ↓ ↑ ↑ 
ǃ-blockers 
(nonselective) 
↑ ↑  ↓  ↑ 
Cardioselective ǃ-
blockers (ǃ1)  
↑ ↑  ↓  ↑ 
Vasodilating ǃ-
blockers  
↓ ↓ ↓ ↓ ↓ ↓ 
ACEI/ARBs ↓ ↓   ↓  
Renin inhibitors Unk. Unk. Unk. Unk. Unk. Unk. 
Calcium channel 
blockers 
↓ ↓ ↓ ↑ ↓ ↓ 
ǂ-antagonists ↓ ↓ ↓ ↑ ↓ ↓ 
Central ǂ-agonists 
(e.g., clonidine) 
neutral neutral neutral neutral neutral neutral 
Where IR=insulin resistance, and Total Chol, HDL-C, LDL-C, and TG are total cholesterol, HDL-
cholesterol, LDL-cholesterol, and triglycerides, respectively. Unk=unknown. ACEI refers to angiotensin 
converting enzyme inhibitors, and ARBs refer to angiotensin receptor blockers.  
1 Thiazide diuretics (especially chlorthalidone) are alternative first choice agents in nondiabetic patients 
but should be used carefully in patients with elevated BMI. In those instances where patients become 
diabetic after initiation of thiazides, an alternative antihypertensive class should be used. For details, see 
text. 
Table 1. Metabolic effects of antihypertensive agents. 
Current treatment recommendations for blood pressure control in patients with diabetes are 
based on these considerations of balancing metabolic, blood pressure, renal, neurologic 
(dizziness) and electrolyte effects. Initial treatment should include RAS blockers (either ACE 
inhibitors or ARBs), followed with a calcium channel blocker or thiazide-like diuretic as 2nd 
line. Current data suggests that the deleterious metabolic effects that may result do not 
override the benefit of blood pressure reduction [3], although the recent ACCOMPLISH 
study (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living 
With Systolic Hypertension) pointed out  that combining the ACE inhibitor benazepril with 
amlodipine, compared to benazepril with hydrochlorothiazide, resulted in benefit in terms 
of reduction in cardiovascular events such as acute clinical events and revascularizations; 
blood pressure was comparable between the two groups [141].  
Lifestyle changes (weight loss, exercise, reduction of alcohol intake, smoking cessation,) 
should not be ignored. Glucose control, while laudable conceptually, may be problematic 
(see elsewhere). Potassium monitoring should continue, and potassium-containing foods 
and use of nonsteroidal antiinflammatories may need to be limited [3]. Combination agents, 
where available, might improve adherence [3]. ǂ–blockers, while powerful in terms of blood 
pressure and prostate effects, may contribute to orthostatic dizziness and may need to be 
limited or avoided [3]. We should not forget that microalbuminuria is a marker of early 
diabetic nephropathy as well as a risk factor for microvascular and macrovascular 
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cardiovascular disease [142] and should be monitored, with efforts expended to mitigate it. 
These overall recommendations are summarized in current American Diabetes Association 
(ADA) guidelines [143]. The Figure represents a treatment strategy derived from ADA (143) 
and other (2) guidelines. 
 
 
Fig. 1. Recommendations for blood pressure control in patients with diabetes (2, 143) 
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4. Genetic markers and treatment of hypertension in patients with the 
metabolic syndrome 
As noted above, treatment of hypertension in the metabolic syndrome can exacerbate other 
of its components (e.g., glucose and lipid control). Further, hypertensive treatment in 
diabetics, may have less than the expected benefit in terms of preventing coronary disease 
and mortality. Is it possible that evolving genetic markers can help guide therapy more 
precisely?   
The INVEST study observed that patients with more severe vascular disease, particularly 
those of Hispanic ethnicity, were at greater risk for developing diabetes, especially with 
hydrochlorothiazide treatment. This risk was attenuated by more aggressive BP control and 
use of a verapamil-trandolapril combination [144]. There is developing data that suggests 
that the CYP3A5 genotype, which does not appear to contribute importantly to the risk of 
hypertension, may influence response to calcium channel blockers [145]. Similarly, the 
KCNMB1 genotype (which contributes to polymorphisms in the large-conductance calcium 
and voltage-dependent potassium channel ǃ1 subunit) may influence response to verapamil 
and potentially adverse outcomes [146].  
Other data from Beitelshees and colleagues suggests that polymorphisms in the CACNA1C 
gene may help identify groups that benefit most from calcium channel blocker therapy, a 
group that benefits from ǃ-blocker therapy, and a third group in which calcium channel 
blocker and ǃ-blocker therapy are equivalent [147]. Similar analyses leading to possible 
future predictions are available for ǃ-blocker treatment outcomes based on ǃ-adrenergic 
receptor gene polymorphisms [148], and promoter polymorphisms in angiotensin-
converting enzyme [149]. This last group of analyses may explain the variation between 
populations in cardiovascular risk and treatment outcomes, since certain alleles are more 
frequent in African-Americans than in either Hispanics or Caucasians [149]. Adducin is a 
ubiquitously expressed cytoskeleton protein that is coded by ADD1. Polymorphisms in this 
gene may lead to increased renal tubular sodium reabsorption and hypertension; certain 
alleles have been shown to manifest an excess risk for a cardiovascular event or death, 
particularly in African-Americans [150]. 
5. Conclusions 
The prevalence of obesity, hypertension and type 2 diabetes mellitus, and, as a consequence, 
the metabolic syndrome, is increasing in the US. In this setting, it is important to individualize 
antihypertensive therapy and to monitor its metabolic consequences so that potential adverse 
effects that would negate some of the benefits of blood-pressure lowering are minimized. 
Strategies to improve blood pressure control in patients with metabolic syndrome, including 
decisions concerning the best pharmacological treatment for these patients, will have major 
morbidity and mortality consequences. The predominance of evidence favors a strategy to 
lower blood pressure to a level approaching the criteria for this syndrome (<130/80) [151, 152]. 
However, a goal blood pressure of <130/80 is not supported by current evidence. In 
hypertensives whose blood pressure is more than 20/10 above target, this frequently will 
require the initiation of a combination of antihypertensives [153].  
Treatment with different antihypertensive drug classes has varied effects on glucose and 
lipid metabolism. Thiazide use in hypertensives has been associated with the development 
of glucose intolerance and diabetes. Studies suggest that the probability of worsening 
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glucose metabolism and the development of new diabetes after thiazide initiation is 
associated with increasing body mass index. Thiazide use also results in small increases in 
total and LDL-cholesterol and triglycerides and decreases in HDL-cholesterol. These 
changes are more pronounced with high dose thiazides.  
Non-selective or ǃ1 selective ǃ-blockers may also lead to decreased insulin sensitivity in 
hypertensive patients. On the other hand, ǃ-blockers, such as carvedilol, that cause 
vasodilatation may not have these deleterious effects on insulin sensitivity and glucose 
metabolism. The effects of ǃ-blockers on lipid metabolism may also vary according to ǃ-
blocker type. Nonselective ǃ-blockers modestly increase serum triglycerides and tend to 
lower HDL-cholesterol, while cardioselective ǃ1-blockers and those without intrinsic 
sympathomimetic activity have qualitatively similar but less pronounced effects. 
Vasodilating ǃ-blockers appear to have even smaller deleterious effects on lipids. 
ACE inhibitors and ARBs may exert beneficial effects on glycemic control through a variety of 
mechanisms related to the inhibition of angiotensin II. These agents may be particularly useful 
in patients with microalbuminuria to slow the progression of renal disease. While there may 
be some small differences among different classes of CCBs, there is little net effect of these 
agents on glucose or lipid metabolism. The ǂ-antagonists generally appear to improve glucose 
and lipid metabolism in diabetic and non-diabetic patients but the increase in cardiovascular 
endpoints in the ALLHAT study with doxazosin suggests that until there is evidence to the 
contrary, this class of antihypertensive should not be used as first line agents. 
The choice of an antihypertensive also has important implications for the cost of medical 
care. Thiazide diuretics and ǃ-blockers are considerably less expensive than most other 
antihypertensive medications and have been shown to be effective antihypertensive 
treatment in several major studies [6, 7, 44]. However, some of the medication cost savings 
would be negated if thiazide and ǃ-blocker use is complicated by an increased probability of 
developing glucose intolerance and even diabetes with its attendant medication and other 
costs associated with its treatment and manifestations. Most of the studies we have 
reviewed have focused on one agent in comparison to another; there is scant data on net 
metabolic effects of combining drug classes. Furthermore, individual patient responses may 
vary from the expected. 
The coexistence of hypertension, dyslipidemia and glucose intolerance increases the risk of 
coronary artery disease, stroke, peripheral vascular disease, nephropathy, neuropathy and 
retinopathy [154-156]. The metabolic syndrome is associated with cardiovascular disease 
and the development of diabetes [157-159]. In treated hypertensive patients, occurrence of 
new diabetes portends a risk for subsequent cardiovascular disease that is similar to that of 
other diabetics [160]. The use of an antihypertensive that results in improvements in 
dyslipidemia, insulin sensitivity and glucose metabolism would be a logical choice in 
patients with metabolic syndrome, but this recommendation needs to be supported with 
clinical trials with hard clinical outcomes, especially total mortality. 
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